Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00366

Submission Number:
00366
Commenter:
Terry Malanda
State:
New Jersey
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
The PBM's are LARGELY responsible for increasing the cost of medications in the US. CVS Caremark is already a restrictive network that limits patient choice and adds no value. ESI should have never been allowed to buy Medco and now CVS should not be allowed to purchase AETNA. These are monopolies, they limit patient choice, increase costs through formularies and "the spread" and are largely UNREGULATED!!! When my husband was seriosly ill, we had an issue with caremark. We wrote the NJ board of pharmacy who claimed they had no jurisdiction over them. So we wrote to the Board of pharmacy where Caremark was located and they said they had no jurisdiction over a NJ resident. We had no protection. While community pharmacies are able to provide prompt service, it takes the large PBM's hours just to receive an order and days to weeks to process it! Stop feeding these beasts and letting them control even more market share!